2021
Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma
Lechner M, Takahashi Y, Turri-Zanoni M, Liu J, Counsell N, Hermsen M, Kaur RP, Zhao T, Ramanathan M, Schartinger VH, Emanuel O, Helman S, Varghese J, Dudas J, Riechelmann H, Sprung S, Haybaeck J, Howard D, Engel NW, Stewart S, Brooks L, Pickles JC, Jacques TS, Fenton TR, Williams L, Vaz FM, O'Flynn P, Stimpson P, Wang S, Hannan SA, Unadkat S, Hughes J, Dwivedi R, Forde CT, Randhawa P, Gane S, Joseph J, Andrews PJ, Royle G, Franchi A, Maragliano R, Battocchio S, Bewicke-Copley H, Pipinikas C, Webster A, Thirlwell C, Ho D, Teschendorff A, Zhu T, Steele CD, Pillay N, Vanhaesebroeck B, Mohyeldin A, Fernandez-Miranda J, Park KW, Le QT, West RB, Saade R, Manes RP, Omay SB, Vining EM, Judson BL, Yarbrough WG, Sansovini M, Silvia N, Grassi I, Bongiovanni A, Capper D, Schüller U, Thavaraj S, Sandison A, Surda P, Hopkins C, Ferrari M, Mattavelli D, Rampinelli V, Facchetti F, Nicolai P, Bossi P, Henriquez OA, Magliocca K, Solares CA, Wise SK, Llorente JL, Patel ZM, Nayak JV, Hwang PH, Lacy PD, Woods R, O'Neill JP, Jay A, Carnell D, Forster MD, Ishii M, London NR, Bell DM, Gallia GL, Castelnuovo P, Severi S, Lund VJ, Hanna EY. Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma. European Journal Of Cancer 2021, 162: 221-236. PMID: 34980502, PMCID: PMC9554673, DOI: 10.1016/j.ejca.2021.09.046.Peer-Reviewed Original ResearchConceptsPeptide radionuclide receptor therapyProphylactic neck irradiationDisease-free survivalOlfactory neuroblastomaSomatostatin receptor 2Stable diseaseAdjuvant radiotherapyNeck irradiationOverall survivalReceptor 2Potential efficacyPeptide receptor radionuclide therapyReceptor radionuclide therapyMultivariable survival analysisPertinent clinical dataClinical trial dataKey prognostic markersNodal recurrenceClinical outcomesClinicopathological characteristicsT stagePrognostic valueReceptor therapyDisease stageNeuroblastoma patients
2019
Margins in Sinonasal Squamous Cell Carcinoma: Predictors, Outcomes, and the Endoscopic Approach
Torabi SJ, Spock T, Cardoso B, Chao J, Morse E, Manes RP, Judson BL. Margins in Sinonasal Squamous Cell Carcinoma: Predictors, Outcomes, and the Endoscopic Approach. The Laryngoscope 2019, 130: e388-e396. PMID: 31755988, DOI: 10.1002/lary.28315.Peer-Reviewed Original ResearchConceptsSinonasal squamous cell carcinomaHigh-volume facilitiesNational Cancer DatabaseSquamous cell carcinomaPositive marginsOverall survivalSurgical approachMargin statusCell carcinomaEthmoid sinusEndoscopic approachMultivariable binary logistic regressionDecreased overall survivalHigher T stageBinary logistic regressionAdditional therapySelect patientsAdult patientsEndoscopic treatmentMultivariable analysisSurgical managementT stageTherapy administrationDifferentiated tumorsOpen surgery
2016
Survival Outcomes for Combined Modality Therapy for Sinonasal Undifferentiated Carcinoma
Kuo P, Manes RP, Schwam ZG, Judson BL. Survival Outcomes for Combined Modality Therapy for Sinonasal Undifferentiated Carcinoma. Otolaryngology 2016, 156: 132-136. PMID: 27703092, DOI: 10.1177/0194599816670146.Peer-Reviewed Original ResearchConceptsSinonasal undifferentiated carcinomaCombined modality therapyNational Cancer DatabaseUndifferentiated carcinomaChemoradiotherapy groupModality therapyOverall survivalSurvival outcomesTreatment modalitiesCancer DatabaseSurvival rateAdjuvant chemotherapy groupImproved survival outcomesMultivariate Cox regressionCumulative survival rateKaplan-Meier analysisMulti-institutional studyCases of SNUCAdjuvant chemotherapyChemotherapy groupMultimodality therapyModality treatmentPrognostic factorsCox regressionAggressive malignancy